Weymouth

Researchers are studying the immune response and safety of mRNA-1018-H5, a pandemic influenza vaccine, in adults aged 18 years and older. The trial aims to assess how well two doses of this vaccine trigger antibody production and to monitor any side effects or reactions. This is a Phase 3, randomized, observer-blind, placebo-controlled study focused on the influenza virus. Participants will receive either the mRNA-1018-H5 vaccine or a placebo, both provided as sterile liquid injections. The study involves two doses and includes detailed monitoring for immune response and side effects after vaccination. The trial compares the vaccine to a placebo to evaluate its immunogenicity and safety. During the study, individuals will undergo medical evaluations including physical exams and pregnancy testing if applicable. Researchers will measure antibody levels at Day 43 and record any local or systemic reactions up to Day 29 after injections, as well as any adverse events up to Day 205. The study tracks serious and medically-attended adverse events to ensure careful safety monitoring throughout the participation period.

Researchers are investigating whether the medicine vicadrostat, when taken together with empagliflozin, can lower the risk of heart-related problems in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. This study is a Phase III trial that compares the effects of vicadrostat plus empagliflozin to a placebo plus empagliflozin in people with these conditions. Participants are randomly assigned to one of two groups: one group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets that look like vicadrostat along with empagliflozin. All participants take one tablet daily for a period ranging from two and a half years up to four years and three months. Throughout the study, participants continue their usual medications for diabetes, high blood pressure, and cardiovascular disease. During up to 51 months of participation, participants visit the study site regularly where doctors collect health information and blood samples. Researchers track when participants experience cardiovascular events such as heart-related deaths or heart failure events. The study also monitors participants’ overall health and any side effects they may experience to assess the safety and effects of the treatments.

Researchers are investigating the Avantect test, a new blood test designed to detect pancreatic cancer early in patients recently diagnosed with type 2 diabetes. Pancreatic cancer is highly lethal, often detected too late for curative treatment. The study focuses on adults aged 50 to 84 years who were diagnosed with type 2 diabetes within the past six months, as this group has a significantly higher risk of undiagnosed pancreatic cancer. The trial aims to evaluate if the Avantect test can identify pancreatic cancer at a treatable stage, potentially improving survival rates. Participants will be randomly assigned to either an intervention group or a control group. Those in the intervention arm will have their blood samples tested with the Avantect device soon after collection. If the test detects biomarkers suggesting pancreatic cancer, participants will be informed and offered imaging scans such as MRI or CT to confirm diagnosis. Control group samples will be stored for future testing or research. The study will enroll up to 15,000 participants over three years. Each participant will attend three study visits over a 12-month period, providing blood samples and completing anxiety questionnaires at every visit. Researchers will follow all participants remotely via cancer and mortality registries for three years after enrollment to track any cancer diagnoses. The main outcomes measured include the sensitivity and specificity of the Avantect test and the rate at which pancreatic cancer can be surgically removed, with analyses planned at six months and at three years.